Genet Med. 2026 Jun 19:102633. doi: 10.1016/j.gim.2026.102633. Online ahead of print.
ABSTRACT
PURPOSE: We aim to better define the genotype and phenotype spectrum of RNU4ATAC-opathy, demonstrate the utility of RNA sequencing for variant classification, and highlight challenges in detecting variants in this noncoding gene.
METHODS: Sixty individuals with molecularly confirmed RNU4ATAC-opathy were recruited from multiple clinical and research centers internationally. RNA sequencing was available for seven affected individuals.
RESULTS: We report the clinical and molecular findings of 60 individuals, including 42 not previously described, and 33 distinct RNU4ATAC variants, 13 of which are novel. Core features in this cohort-present in most individuals assessed and varying in severity-include microcephaly, short stature, skeletal anomalies, developmental delay, cerebral anomalies, skin conditions and immune deficiency. Additional findings such as diabetes, holoprosencephaly, and absence of various core features in some individuals highlight the broad phenotypic spectrum. All individuals with RNA sequencing showed a consistent pattern of minor intron retention. In six, RNA-seq enabled reclassification of variants of uncertain significance as likely pathogenic. While RNU4ATAC variants are generally covered by clinical exomes, they are often overlooked in analysis due to the noncoding nature.
CONCLUSION: This study further highlights the variability of phenotypes and genotypes associated with RNU4ATAC-opathy. Laboratories should ensure RNU4ATAC and other noncoding genes are appropriately assessed by their analysis pipelines.
PMID:42322193 | DOI:10.1016/j.gim.2026.102633